David M Brown Selected Research

Retinal Vein Occlusion

10/2022	RETINAL VASCULAR BED AREA IN EYES WITH RETINAL VEIN OCCLUSION ON ULTRA-WIDEFIELD FLUORESCEIN ANGIOGRAPHY: WAVE Study.
1/2018	Suprachoroidal Triamcinolone Acetonide for Retinal Vein Occlusion: Results of the Tanzanite Study.
1/2018	Changes in retinal ischaemic index correlate with recalcitrant macular oedema in retinal vein occlusion: WAVE study.
1/2017	Peripheral Laser for Recalcitrant Macular Edema Owing to Retinal Vein Occlusion: The WAVE Trial.
2/2016	Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52-Week Results of the VIBRANT Study.
3/2015	Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study.
1/2015	Progressive retinal nonperfusion in ischemic central retinal vein occlusion.
9/2014	Ranibizumab in preproliferative (ischemic) central retinal vein occlusion: the rubeosis anti-VEGF (RAVE) trial.
7/2014	Intravitreal aflibercept injection for macular edema due to central retinal vein occlusion: two-year results from the COPERNICUS study.
1/2014	Long-term outcomes in patients with retinal vein occlusion treated with ranibizumab: the RETAIN study.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

David M Brown Research Topics

Disease

50	Macular Edema 07/2023 - 03/2007
39	Macular Degeneration (Age-Related Maculopathy) 03/2024 - 10/2006
21	Diabetic Retinopathy (Retinopathy, Diabetic) 01/2022 - 03/2007
15	Retinal Vein Occlusion 10/2022 - 06/2010
13	Inflammation (Inflammations) 03/2024 - 01/2003
7	Endophthalmitis (Ophthalmia) 01/2020 - 10/2006
6	Choroidal Neovascularization 05/2021 - 10/2006
5	Neoplasms (Cancer) 01/2017 - 07/2005
5	Infections 05/2013 - 02/2004
4	Stroke (Strokes) 01/2018 - 04/2012
3	Hemorrhage 05/2024 - 10/2007
3	Ischemia 10/2022 - 01/2013
3	Edema (Dropsy) 01/2018 - 01/2014
3	Pancreatic Neoplasms (Pancreatic Cancer) 01/2017 - 04/2009
3	Uveitis 03/2013 - 10/2006
3	Necrosis 09/2011 - 01/2003
2	Choroidal Effusions 03/2024 - 01/2018
2	Retinal Diseases 01/2023 - 08/2017
2	Geographic Atrophy 01/2020 - 04/2011
2	Ischemic Stroke 01/2018 - 04/2012
2	Atrophy 01/2018 - 01/2013
2	Nausea 01/2017 - 08/2012
2	Ovarian Neoplasms (Ovarian Cancer) 01/2017 - 07/2005
2	Malaria 04/2013 - 01/2003
2	Prostatic Neoplasms (Prostate Cancer) 08/2010 - 07/2005
1	Substernal Goiter 05/2024
1	Hematoma 05/2024
1	HIV Infections (HIV Infection) 12/2022
1	Carotid-Cavernous Sinus Fistula 01/2022
1	Retinal Vasculitis 01/2022
1	Diabetes Mellitus 01/2021
1	Cataract (Cataracts) 10/2018
1	Body Weight (Weight, Body) 01/2018
1	Microaneurysm 01/2017
1	Muscle Cramp (Cramp) 01/2017
1	Fatigue 01/2017
1	Diarrhea 01/2017
1	Anorexia 01/2017

Drug/Important Bio-Agent (IBA)

33	afliberceptIBA 07/2023 - 06/2011
33	Ranibizumab (Lucentis)FDA Link 01/2019 - 10/2006
31	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 03/2024 - 10/2006
20	Retinaldehyde (Retinal)IBA 03/2024 - 03/2007
11	Fluorescein (Funduscein)FDA LinkGeneric 10/2022 - 01/2013
9	salicylhydroxamic acid (SHAM)IBA 05/2021 - 10/2006
5	brolucizumabIBA 07/2023 - 01/2020
5	CytokinesIBA 10/2022 - 06/2010
4	Biomarkers (Surrogate Marker)IBA 10/2022 - 01/2021
4	Fluocinolone Acetonide (Capex)FDA LinkGeneric 03/2013 - 07/2010
4	Verteporfin (Visudyne)FDA Link 10/2010 - 10/2006
3	Endothelial Growth FactorsIBA 01/2022 - 10/2010
3	Triamcinolone Acetonide (Azmacort)FDA LinkGeneric 01/2018 - 01/2018
3	phenoxodiolIBA 08/2010 - 07/2005
2	MetalsIBA 08/2021 - 05/2005
2	CopperIBA 08/2021 - 01/2018
2	OxidesIBA 08/2021 - 01/2018
2	SuspensionsIBA 01/2018 - 09/2010
2	N-acetyltryptophanamide (NATA)IBA 01/2018 - 08/2017
2	Tissue Plasminogen Activator (Alteplase)FDA Link 01/2018 - 04/2012
2	CaspasesIBA 01/2017 - 09/2011
2	Anti-Bacterial Agents (Antibiotics)IBA 07/2016 - 04/2013
2	Bevacizumab (Avastin)FDA Link 01/2016 - 10/2010
2	Hormones (Hormone)IBA 02/2013 - 07/2005
2	triphendiolIBA 09/2011 - 04/2009
2	Gemcitabine FDA Link 09/2011 - 04/2009
2	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 06/2010 - 01/2003
2	IsoflavonesIBA 04/2009 - 07/2005
2	FlavonoidsIBA 04/2009 - 07/2005
2	1-phenyl-3,3-dimethyltriazene (PDT)IBA 01/2009 - 12/2007
2	Monoclonal AntibodiesIBA 10/2006 - 10/2006
2	Reactive Oxygen Species (Oxygen Radicals)IBA 10/2005 - 01/2003
1	Angiopoietin-2IBA 01/2023
1	Broadly Neutralizing AntibodiesIBA 12/2022
1	Leukotriene B4IBA 01/2022
1	Neurofibromin 2 (Merlin)IBA 01/2022
1	Indocyanine Green (Cardio-Green)FDA LinkGeneric 01/2022
1	Immunoglobulin FragmentsIBA 01/2020
1	pegcetacoplanIBA 01/2020
1	Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA 01/2020
1	Complement C3 (C3 Complement)IBA 01/2020
1	Myosin Heavy Chains (Myosin Heavy Chain)IBA 01/2018
1	MyogeninIBA 01/2018
1	ClenbuterolIBA 01/2018
1	Hemoglobins (Hemoglobin)IBA 09/2017
1	Cisplatin (Platino)FDA LinkGeneric 01/2017
1	4- (para- hydroxyphenyl)- 7,4'- dihydroxy- 3',5'- dimethoxy- 8- methylisoflavanIBA 01/2017
1	Carboplatin (JM8)FDA LinkGeneric 01/2017
1	Transaminases (Aminotransferases)IBA 01/2017

Therapy/Procedure

20	Therapeutics 01/2023 - 07/2005
17	Injections 03/2024 - 10/2006
13	Lasers (Laser) 01/2019 - 03/2007
9	Light Coagulation 10/2018 - 03/2007
7	Intravitreal Injections 01/2021 - 10/2006
4	Photochemotherapy (Photodynamic Therapy) 10/2010 - 10/2006
3	Intraocular Injections 10/2011 - 06/2010
2	Drug Therapy (Chemotherapy) 07/2005 - 01/2003
1	Thyroidectomy 05/2024
1	Cautery 05/2024
1	Vitrectomy 03/2024
1	Retreatment 01/2018
1	Glycemic Control 09/2017